Core Viewpoint - Allogene Therapeutics (ALLO) has experienced a significant decline of 31.9% over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Stock Performance and Technical Indicators - ALLO's stock has been under heavy selling pressure, leading to an RSI reading of 25.87, indicating it is oversold [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold conditions when the reading falls below 30 [2]. - Stocks oscillate between overbought and oversold states, and an oversold condition may present entry opportunities for investors anticipating a rebound [3]. Group 2: Analyst Sentiment and Earnings Estimates - There is a strong consensus among sell-side analysts to raise earnings estimates for ALLO, resulting in a 0.4% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [7]. - ALLO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) has experienced significant selling pressure, resulting in a 15.6% decline in stock price over the past four weeks, but analysts anticipate improved earnings reports in the near future [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - TARS has an RSI reading of 29.83, suggesting that the heavy selling may be exhausting, potentially leading to a price rebound [5] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for TARS by 19.5% over the last 30 days, indicating a positive trend that typically correlates with price appreciation [6] - TARS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround [7]

A downtrend has been apparent in New Jersey Resources (NJR) lately with too much selling pressure. The stock has declined 5.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicato ...

Core Viewpoint - Investors should focus on pharmaceutical stocks that are currently trading at extremely oversold levels, as indicated by the Relative Strength Index (RSI), which can signal potential rebounds [1][13]. Group 1: Sarepta Therapeutics - Sarepta Therapeutics has an RSI of 22, indicating extreme oversold conditions, and has seen its stock price drop over 40% following an earnings miss [2][3]. - The 12-month stock price forecast for Sarepta is $131.22, suggesting a potential upside of 262.48% from the current price of $36.20 [2]. - Analysts, including those from Wells Fargo, maintain a Buy rating and are optimistic about Sarepta's long-term pipeline, particularly its FDA-approved gene therapy for Duchenne muscular dystrophy [3][4]. Group 2: Krystal Biotech - Krystal Biotech's RSI has risen to 33, indicating a recovery from oversold levels, with a recent stock price of $134.53 [5][6]. - The 12-month stock price forecast for Krystal is $218.63, representing a potential upside of 62.51% [5]. - Analysts remain bullish on Krystal, with Guggenheim reiterating a Buy rating and a price target of $189, indicating nearly 40% upside potential [7][8]. Group 3: Lantheus Holdings - Lantheus Holdings has an RSI of 28, showing signs of being oversold after a 25% drop following an earnings miss [9][10]. - The 12-month stock price forecast for Lantheus is $132.67, suggesting a potential upside of 68.04% from the current price of $78.95 [9]. - Truist Financial has reiterated a Buy rating with a price target of $117, indicating more than 45% upside potential, supported by the company's strong product portfolio [11][10].

Sera Prognostics, Inc. (SERA) has been beaten down lately with too much selling pressure. While the stock has lost 30.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

Core Viewpoint - AZUL has experienced significant selling pressure, declining 57.1% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, supported by positive earnings forecasts from Wall Street analysts [1]. Group 1: Stock Performance - AZUL's stock has declined 57.1% in the last four weeks, indicating substantial selling pressure [1]. - The stock's Relative Strength Index (RSI) is currently at 23.35, suggesting it is oversold and may soon experience a trend reversal [5]. Group 2: Analyst Sentiment - There is strong consensus among sell-side analysts that AZUL will report better earnings than previously predicted, with the consensus EPS estimate increasing by 8.3% over the last 30 days [7]. - AZUL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - LifeStance Health Group (LFST) is experiencing significant selling pressure, with a 20.3% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by positive earnings expectations from Wall Street analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with readings below 30 indicating oversold conditions [2]. - LFST's current RSI reading is 27.4, suggesting that the heavy selling may be exhausting, indicating a potential bounce back towards previous supply and demand equilibrium [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that LFST will report better earnings than previously predicted, with a 2.5% increase in the consensus EPS estimate over the last 30 days [7]. - LFST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Core Insights - Uber Technologies Inc's stock is down 1.4% to $84.65 following mixed first-quarter results, with earnings of 83 cents per share exceeding the Zacks Research estimate of 51 cents, while revenue of $11.53 billion slightly missed expectations [1] Group 1: Stock Performance - Today's decline interrupts a three-day winning streak for Uber's stock, which reached highs around $86.50 in the previous sessions but could not surpass the record high of $87 set on October 11 [2] - Since the beginning of the year, Uber's stock has increased by 40.7%, indicating strong year-to-date performance [2] - The stock's 14-day relative strength index (RSI) is at 79, nearing "oversold" territory, suggesting that the current pullback may have been anticipated [2] Group 2: Options Activity - In the options market, there has been significant activity with 150,000 calls and 63,000 puts traded, which is four times the typical overall options volume for this period [3] - The most popular option is the May 87.50 call, followed by the weekly 5/9 80-strike put, with new positions being opened in the latter [3]

Core Viewpoint - HealthStream (HSTM) has experienced a significant downtrend, with a 13.2% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1] Group 1: Stock Performance - HSTM's stock has faced heavy selling pressure, leading to a decline of 13.2% in the last month [1] - The stock's Relative Strength Index (RSI) is currently at 25.2, indicating it is oversold and may soon reverse its trend [5] Group 2: Analyst Sentiment - There is a strong consensus among sell-side analysts regarding HSTM's ability to exceed previous earnings estimates, with a 0.5% increase in the consensus EPS estimate over the last 30 days [7] - HSTM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a potential rebound [8]

Group 1 - AMD is set to report its first-quarter earnings, with Wall Street expecting earnings per share of 94 cents and revenue of $7.13 billion [1] - The stock has increased by 20.27% over the past month, but is down 16.61% year to date and 35.43% from the previous year [1] - Between March 2024 and early April 2025, AMD lost 62% of its market capitalization, but signs of recovery are emerging [2] Group 2 - AMD stock is currently trading at $100.59, showing strong short-term momentum above its five-day, 20-day, and 50-day exponential moving averages [3] - The stock is below its 200-day simple moving average of $128.51, indicating a bearish long-term signal, although the MACD indicator is bullish at 0.24 [4] - The Relative Strength Index (RSI) is at 56.32, suggesting the stock is neither overbought nor oversold [4] Group 3 - Analysts have a consensus rating of "Buy" for AMD stock, with a price target of $143.60, indicating a potential upside of 26% [5] - Recent analyst calls average a price target of $125.67, suggesting an implied upside of 25.89% from current levels [5]